Merck’s Pifeltro (doravirine) Receives FDA Approval for Patients with HIV-1 in Appropriate Patients

 Merck’s Pifeltro (doravirine) Receives FDA Approval for Patients with HIV-1 in Appropriate Patients

Merck’s Pifeltro (doravirine) Receives FDA Approval for Patients with HIV-1 in Appropriate Patients

Shots:

  • The approval is based on P-III DRIVE-FORWARD study assessing Pifeltro (qd) vs darunavir + ritonavir (DRV+r) (800mg, 100 mg, qd) each in combination with emtricitabine (FTC)/TDF or abacavir (ABC)/3TC in patients with HIV-1 infection
  • P-III DRIVE-FORWARD study results: @48 wks. viral suppression of HIV-1 RNA <40 copies/mL (83% vs  79%); @96 wks. (72% vs 64%); patients discontinued treatment (2% vs 3%) ; LDL-cholesterol and non-HDL-cholesterol (-4.6,-5.4 mg/DL vs 9.5, 13.7 mg/DL)
  •  Pifeltro (doravirine, 100mg) is a qd NNRTI in combination with antiretroviral medicines indicated and approved for the HIV-1 infection

Click here to read full press release/ article | Ref: Merck | Image: Glassdoor

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post